UNDERWRITING AGREEMENT between LANTERN PHARMA INC and THINKEQUITY A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC. as Representative of the Several Underwriters LANTERN PHARMA INC.Underwriting Agreement • January 8th, 2021 • Lantern Pharma Inc. • Pharmaceutical preparations • New York
The undersigned, Lantern Pharma Inc., a corporation formed under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being a subsidiary or affiliates of Lantern Pharma Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity, a division of Fordham Financial Management, Inc., (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
SECOND ADDENDUM TO TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • January 8th, 2021 • Lantern Pharma Inc. • Pharmaceutical preparations
This Second Addendum to Technology License Agreement (“Second Addendum”) is entered into by and between AF Chemicals, LLC (“AFC”) and Lantern Pharma Inc. (“LANTERN”) as of the 30th day of December of the year 2020 (“Second Addendum Effective Date”).
